Abstract
Glycobiomarkers are valuable for disease diagnostics, monitoring and prognostics with greater sensitivity and specificity than the currently used biomarkers. For liver diseases diagnostics, Wisteria floribunda agglutinin (WFA)-positive human Mac-2-binding protein, fucosylated haptoglobin, vitronectin, antithrombin III, WFA-positive colony stimulating factor 1 receptor and fucosylated hemopexin were recently reported to be promising glycobiomarkers, including fucosylated serum paraoxonase 1 and fucosylated GP73 in our previous studies. Large-scale validation and clinical trials of most glycobiomarkers are urgently needed for crossing the boundary from the laboratory into routine clinical use.